Ecuador Transition Filing Strategy 2026–2027: Reclassification and ISO 13485 Substitution

1. Key takeaways

The new regulation enters into force on 2027-01-28, and its transitional provisions (Disposiciones Transitorias) make three arrangements: ARCSA must issue the implementing instructions within 9 months of signature; ARCSA will proactively reclassify existing valid certificates in accordance with those instructions, while holders may also apply proactively for reclassification through a variation application, at no fee whatsoever; and until the technical standard for good manufacturing practice of devices is issued, domestic manufacturers may substitute an ISO 13485 certificate issued by designated bodies. Transition decisions should be taken product family by product family according to the completeness of the available evidence.

2. Legal basis

Key points of the transitional provisions (substance of the official text):

• Item 1: ARCSA must issue the implementing instructions (instructivos) within 9 months of signature;
• Item 2: ARCSA will announce through its website the list of devices requiring adjustment; holders of products to be reclassified must verify that the products meet the requirements of the current regulation and submit the information requested by ARCSA; reclassification is requested through a variation application and no fee is charged; if reclassification concludes that a product is not a medical device, ARCSA will notify the holder through the document management system (Quipux);
• Item 3: until the technical standard for good manufacturing practice (BPM) of devices is issued, domestic manufacturers may substitute an ISO 13485 certificate issued by a body recognized by SAE or designated by MPCEI; ARCSA may conduct pre-market laboratory testing of domestically manufactured products.

3. Expert insights

Insight 1: free reclassification is the most important official commitment of the transition period. Transitional provision 2 states in its original wording that the variation application is not subject to any payment (misma que no estará sujeta a pago alguno). This means that class changes of existing certificates caused by the new classification rules do not cost the company anything, which is uncommon in Latin American regulatory transitions. Multi-product-line holders should consolidate their reclassification applications to consume the window efficiently rather than dispersing them across separate projects.

Insight 2: ARCSA will reclassify proactively, but this does not waive the holder’s documentation obligations. Transitional provision 2 also provides that holders of reclassified products must verify that the products comply with the requirements of the current regulation and submit the information ARCSA requires. In other words: the classification adjustment is initiated by ARCSA and free of charge, but the obligation to complete the compliance documentation remains with the company. A reclassification notice is therefore the trigger for a documentation project, not merely an administrative note.

Insight 3: the 9-month instruction-issuance period is the critical time window and the main source of uncertainty. Transitional provision 1 requires ARCSA to issue the implementing instructions within 9 months of signature, that is before 2027-01-28. These instructions will settle matters not defined in the body text, such as classification details, tiered technical documentation requirements and the boundary of low-risk devices. Until they appear, several filing decisions can only be taken provisionally and revisited.

Insight 4: transitional provision 3 opens a temporary channel for domestic (local) manufacturers. Until the device BPM technical standard is issued, an ISO 13485 certificate issued by an SAE-recognized or MPCEI-designated body may substitute for the BPM requirement. This is a substantive benefit for Chinese manufacturers planning local production in Ecuador, but it does not apply to purely export-oriented manufacturers whose products are manufactured abroad and enter the market through import channels.

Insight 5: the regulation contains no express transitional arrangement for applications filed before the effective date. This point must follow subsequent ARCSA publications. The conservative approach is to assume that applications filed after the effective date fall under the new law, that applications filed before it are governed by the law in force at acceptance, and to maintain a register of pending applications with proof of submission. Filing receipts and system timestamps become the decisive evidence in any dispute over applicable law.

4. Practical recommendations

1. Decide product family by product family on evidence readiness:
   • Class I–IV products holding a high vigilance agency registration and commercialized in IMDRF member jurisdictions: evaluate waiting for the simplified channel;
   • Class III/IV products without international certificates: start under the current regulation and reserve time for dossier rework;
   • Large IVD families: build the one-certificate-many-models architecture now (the Article 14 logic works under both regimes).
2. Track the implementing instructions ARCSA issues before 2027-01-28 and complete an internal gap analysis within 30 days of each issuance.
3. Holders of existing certificates should monitor the reclassification list announcements on the website and submit verification documentation promptly upon notice.
4. Use the free reclassification window proactively to adjust classes rather than waiting passively, processing multiple product lines together.
5. Manufacturers producing in Ecuador should evaluate the ISO 13485 substitution channel of transitional provision 3.

5. Verification checklist

• □ Confirmed the position of the effective date 2027-01-28 relative to the project schedule
• □ Completed product-family decisions based on evidence readiness
• □ Established tracking of ARCSA implementing instructions (before 2027-01-28)
• □ Brought existing certificates under monitoring of the reclassification list
• □ Confirmed the conditions and application path of free reclassification
• □ Manufacturers producing in Ecuador have evaluated the substitution channel of transitional provision 3

Regulatory information verified as of October 29, 2026

Core service areas

1. Global market access: EU CE (MDR/IVDR), US FDA (510(k)/De Novo/PMA), UK UKCA, Australia TGA, Canada Health Canada, Brazil ANVISA and Russia RZN, plus premarket registration pathway planning and filing execution across Latin America, Southeast Asia, the Middle East and other markets.
2. Authorized representative services: EU authorized representative (EC REP), UK responsible person (UK RP), Swiss authorized representative (CH REP), Australia sponsor and US Agent, together with neutral certificate-holder structure design.
3. Quality system compliance: ISO 13485 implementation and maintenance, MDSAP audit preparation, GMP conformity coaching, and technical documentation (TD) authoring and remediation.
4. Clinical and evaluation: clinical evaluation plans (CEP) and reports (CER), equivalence argumentation, PMCF planning and execution, and IVD performance evaluation.
5. Post-market compliance: vigilance and adverse event reporting, FSCA and recall execution, registration change and renewal management, and maintenance of national regulatory databases.

Why GRZAN

• Local regulatory teams: filings in each target market are executed by locally licensed regulatory professionals and prepared directly in the official language of the market, without secondary translation.
• Neutral holding structure: certificate-holding arrangements that are not tied to any distribution channel, keeping registrations independent of channel partners.
• Regional leverage: a single technical dossier can be reused across Andean Community and Mercosur member states, spreading regional compliance cost.
• Full lifecycle support: end-to-end service from classification, pathway design and dossier preparation through certificate holding, customs clearance, post-market vigilance and renewal.

Contact

• GRZAN provides medical device registration support in Ecuador for manufacturers, importers and authorized representatives.
• Email: info@grzanglobal.com
• Service inquiries: Ecuador and Andean market registration plans, certificate-holding structure design, official fee and timeline estimation